{"database": "lobbying", "table": "lobbying_activities", "rows": [[1560208, "861201e9-c907-4910-8de8-49c7eeed82fb", "Q2", "BROWN RUDNICK LLP", 287895, "APOTEX CORPORATION", 2014, "second_quarter", "PHA", "Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-07-18T12:44:17.420000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1560208"], "units": {}, "query_ms": 1.2042050366289914, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}